There is abundant evidence of elevated platelet activation and degranulation in SCD in vivo (84, 85); preclinical and early-phase studies have demonstrated that P2Y12 antagonists decrease platelet activation and inflammatory signaling in murine models and human in vitro models of SCD (47–49). The gene discussed is P2RY12; the disease is Schnyder corneal dystrophy.